Trade Setup Buy Target $9.34 Sell Target $12.41 Stop Loss $7.44 Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and […]
Read MoreTrade Setup Buy Target $1.52 Sell Target $1.68 Trailing Stop 20% vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III […]
Read MoreTrade Setup Buy Target $11.27 Sell Target $12.83 Trailing Stop 20% Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States.
Read MoreTrade Setup Buy Target $0.93 Sell Target 1 $1.22 Trailing Stop 20% Sell Target 2 $1.42 Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company develops products using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals, which could […]
Read MoreTrade Setup Buy Target $2.80 Sell Target 1 $3.34 Trailing Stop 20% Sell Target 2 $3.72 Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized […]
Read MoreIn the last week I’ve been focusing my attention in this space on a few of the biggest, most established names in the pharmaceutical space. It’s an industry that I think is becoming more interesting under current market conditions, as some of these names remain significantly off of multi-year, or even all-time highs even as […]
Read MoreOver the last week, one of the fears that has been driving the market (besides the new constant, which is trade) is the concern over whether the economy is finally at risk to start weakening. For some investors, that fear has led to a “flight to quality,” meaning that they’re starting to look for safe […]
Read MoreThese 2 biotech stocks could see double-digit upside over the next year.
Read MoreTrade Setup Buy Target $2.80 Sell Target 1 $3.34 Trailing Stop 20% Sell Target 2 $3.72 Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized […]
Read MoreIt seems that the only news anybody really cares about right now is the trade war. China announced yesterday that it would impose $60 billion of retaliatory tariffs against the U.S. after the Trump administration increased already imposed duties from 10% to 25% at the end of last week. That has propelled the market to […]
Read MoreAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients […]
Read MoreThese 3 stocks look like bargains at these levels and could soon surge far higher.
Read MoreBoth have catalysts coming up that could make them prime candidates for a buyout.
Read MoreThis small but promising biotech recently had its U.S. debut and analysts say it could deliver a triple-digit return over the next twelve months.
Read MoreGT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms. The company develops immuno-oncology product candidates, including OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors; OXS-3550, a […]
Read More